- Home
- ORKA vs ZBIO Comparison
ORKA vs ZBIO Comparison
Compare ORKA & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- ZBIO
- Stock Information
- Founded
- ORKA 2004
- ZBIO 2019
- Country
- ORKA United States
- ZBIO United States
- Employees
- ORKA N/A
- ZBIO N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ZBIO
- Sector
- ORKA Health Care
- ZBIO
- Exchange
- ORKA Nasdaq
- ZBIO NYSE
- Market Cap
- ORKA 354.2M
- ZBIO 389.2M
- IPO Year
- ORKA N/A
- ZBIO 2024
- Fundamental
- Price
- ORKA $10.96
- ZBIO $9.52
- Analyst Decision
- ORKA Strong Buy
- ZBIO Strong Buy
- Analyst Count
- ORKA 8
- ZBIO 7
- Target Price
- ORKA $39.71
- ZBIO $32.29
- AVG Volume (30 Days)
- ORKA 143.0K
- ZBIO 130.3K
- Earning Date
- ORKA 05-14-2025
- ZBIO 05-15-2025
- Dividend Yield
- ORKA N/A
- ZBIO N/A
- EPS Growth
- ORKA N/A
- ZBIO N/A
- EPS
- ORKA N/A
- ZBIO N/A
- Revenue
- ORKA N/A
- ZBIO $15,000,000.00
- Revenue This Year
- ORKA N/A
- ZBIO N/A
- Revenue Next Year
- ORKA N/A
- ZBIO N/A
- P/E Ratio
- ORKA N/A
- ZBIO N/A
- Revenue Growth
- ORKA N/A
- ZBIO N/A
- 52 Week Low
- ORKA $5.49
- ZBIO $5.83
- 52 Week High
- ORKA $52.32
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- ZBIO N/A
- Support Level
- ORKA N/A
- ZBIO N/A
- Resistance Level
- ORKA N/A
- ZBIO N/A
- Average True Range (ATR)
- ORKA 0.00
- ZBIO 0.00
- MACD
- ORKA 0.00
- ZBIO 0.00
- Stochastic Oscillator
- ORKA 0.00
- ZBIO 0.00
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.